Roth MKM Reinstates Buy on Journey Medical, Announces $11 Price Target
Benzinga Newsdesk 2 years ago
NewsPrice TargetInitiationAnalyst Ratings
Roth MKM analyst Jason Wittes reinstates Journey Medical (NASDAQ:DERM) with a Buy and announces $11 price target.
Roth MKM analyst Jason Wittes reinstates Journey Medical (NASDAQ:DERM) with a Buy and announces $11 price target.